RESOLVED, IPO opposes the “Bill to Address Patent Thickets” (S. 3583) and any substantially similar versions of the legislation because (1) it unnecessarily limits patent owners from asserting more than one patent per “Patent Group” against an alleged infringer in a Hatch-Waxman or Biologics Price Competition and Innovation Act (BPCIA) litigation, and (2) existing statutory frameworks and district court case management procedures work well to narrow the number of patents and claims asserted in such cases.